Hepatitis B virus epidemiology, disease burden, treatment, arid current and emerging prevention and control measures

Journal of Viral Hepatitis

Volumn 11, Issue 2, 2004, Pages 97-107

  Lavanchy, D ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Adefovir; Cirrhosis; Hepatitis B infection; Hepatitis B vaccine; Hepatocellular carcinoma; Interferon alfa; Lamivudine; Peginterferon alfa 2a (40 kDA)

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA2A INTERFERON; ENTECAVIR; GAMMA INTERFERON ANTIBODY; HEPATITIS B VACCINE; LAMIVUDINE; PEGINTERFERON ALPHA2A;

ANTIBIOTIC RESISTANCE; CANCER INCIDENCE; CANCER REGISTRY; CHRONIC HEPATITIS; COST BENEFIT ANALYSIS; DISEASE ASSOCIATION; DRUG HALF LIFE; ENDEMIC DISEASE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION COMPLICATION; INFECTION CONTROL; INFECTION PREVENTION; LIVER CARCINOMA; PARASITE PREVALENCE; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; SIDE EFFECT; VERTICAL TRANSMISSION; VIRAL CONTAMINATION; VIREMIA; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; INTERFERON-ALPHA; LAMIVUDINE; LIVER CIRRHOSIS; POLYETHYLENE GLYCOLS;

EID: 1642410856     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2003.00487.x     Document Type: Review

References (90)

1. World Health Organization: The World Health Report. 1997. World Health Organization, Geneva, Switzerland.
2. World Health Organization. Hepatitis B. World Health Organization Fact Sheet 204 (Revised October 2000). WHO Web site. 2000. http://who.int/inf-fs/en/ fact204.html.
3. Liaw YF, Leung NW, Chang TT et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119(1): 172-180.
4. Lok AS, Hussain M, Cursano C et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000; 32(5): 1145-1153.
5. Yang H, Westland CE, Delaney WE et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002; 36(2): 464-473.
6. de Man RA, Wolters LM, Nevens F et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 2001; 34(3): 578-582.
7. Cooksley WG, Piratvisuth T, Lee SD et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003; 10(4): 298-305.
8. Lok AS. Chronic hepatitis B. N Engl J Med 2002; 346(22): 1682-1683.
9. Mahoney FJ. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev 1999; 12(2): 351-366.
10. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337(24): 1733-1745.
11. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94(2): 153-156.
12. Yu MC, Yuan JM, Govindarajan S, Ross RK. Epidemiology of hepatocellular carcinoma. Can J Gastroenterol 2000; 14(8): 703-709.
13. World Health Organization. Hepatitis B Vaccines. WHO Web site. 2003. http://www.who.int/vaccines/en/hepatitisb. shtml.
14. World Health Organization. Childhood diseases in Africa. 1996. World Health Organization, Geneva, Switzerland. Fact Sheet N109. http://www.who.int/ inf-fs/en/fact109.html.
15. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2001; 120(7): 1828-1853.
16. McGlynn KA, Tsao L, Hsing AW, et al. International trends and patterns of primary liver cancer. Int J Cancer 2001; 94(2): 290-296.
17. Lemon SM, Layden TJ, Seeff L, et al. The 20th United States-Japan Joint Hepatitis Panel Meeting. Hepatology 2000; 31(3): 800-806.
18. Gust ID. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut 1996; 38(Suppl 2): S18-23.
19. Chen CJ, Wang LY, Yu MW. Epidemiology of hepatitis B virus infection in the Asia-Pacific region. J Gastroenterol Hepatol 2000; 15(Suppl.): E3-6.
20. Simonsen L, Kane A, Lloyd J et al. Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull World Health Organ 1999; 77(10): 789-800.
21. Kane A, Lloyd J, Zaffran M et al. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. Bull World Health Organ 1999; 77(10): 801-807.
22. Schmunis GA, Zicker F, Cruz JR, Cuchi P. Safety of blood supply for infectious diseases in Latin American countries, 1994-1997. Am J Trop Med Hyg 2001; 65(6): 924-930.
23. Carman WF, Jacyna MR, Hadziyannis S et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2(8663): 588-591.
24. Beasley R, Hwang L.-Y. Overview of the Epidemiology of Hepatocellular Carcinoma. Baltimore: 1991.
25. Hsieh CC, Tzonou A, Zavitsanos X et al. Age at first establishment of chronic hepatitis B virus infection and hepatocellular carcinoma risk. A birth order study. Am J Epidemiol 1992; 136(9): 1115-1121.
26. McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001; 135(9): 759-768.
27. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340(10): 745-750.
28. Pokorski RJ, Ohlmer U. Long-term morbidity and mortality in Chinese insurance applicants infected with the hepatitis B virus. J Insur Med 2001; 33(2): 143-164.
29. Uzunalimoglu O, Yurdaydin C, Cetinkaya H et al. Risk factors for hepatocellular carcinoma in Turkey. Dig Dis Sci 2001; 46(5): 1022-1028.
30. Stroffolini T, Andreone P, Andriulli A et al. Characteristics of hepatocellular carcinoma in Italy. J Hepatol 1998; 29(6): 944-952.
31. Kuper HE, Tzonou A, Kaklamani E et al. Hepatitis B and C viruses in the etiology of hepatocellular carcinoma: a study in Greece using third-generation assays. Cancer Causes Control 2000; 11(2): 171-175.
32. Brechot C, Jaffredo F, Lagorce D et al. Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action. J Hepatol 1998; 29(2): 173-183.
33. Brooks EA, Lacey LF, Payne SL, Miller DW. Economic evaluation of lamivudine compared with interferon-alpha in the treatment of chronic hepatitis B in the United States. Am J Manag Care 2001; 7(7): 677-682.
34. Metcalf M, Brown N, Peterson S et al. Health care costs associated with chronic hepatitis B. Am J Health Syst Pharm 1999; 56(3): 232-236.
35. Margolis HS, Schatz GC, Kane MA. Development of recommendations for control of hepatitis B virus infections: the role of cost analysis. Vaccine 1990; 8(Suppl.): S69-73; discussion S93-94.
36. Rosenberg D, Cook S, Eaton S et al. The epidemiology, treatment patterns and resource utilization of hepatitis B patients in a large insured New England population. Pharmcoepidmiol Drug Saf 1998; 7(Suppl. 2): S132.
37. Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995; 122(9): 664-675.
38. Shiell A, Briggs A, Farrell GC. The cost effectiveness of alpha interferon in the treatment of chronic active hepatitis C. Med J Aust 1994; 160(5): 268-272.
39. Yang BM, Paik SW, Hahn OS et al. Economic evaluation of the societal costs of hepatitis B in South Korea. J Gastroenterol Hepatol 2001; 16(3): 301-308.
40. Ni YH, Chang MH, Huang LM et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med 2001; 135(9): 796-800.
41. Chen HL, Chang MH, Ni YH et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA 1996; 276(11): 906-908.
42. Chen DS, Hsu NH, Sung JL et al. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. JAMA 1987; 257(19): 2597-2603.
43. Hsu HM, Chen DS, Chuang CH et al. Efficacy of a mass hepatitis B vaccination program in Taiwan. Studies on 3464 infants of hepatitis B surface antigen-carrier mothers. JAMA 1988; 260(15): 2231-2235.
44. Aguayo A, Patt YZ. Liver cancer. Clin Liver Dis 2001; 5(2): 479-507.
45. Chang MH, Chen CJ, Lai MS et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336(26): 1855-1859.
46. Lee MS, Kim DH, Kim H et al. Hepatitis B vaccination and reduced risk of primary liver cancer among male adults: a cohort study in Korea. Int J Epidemiol 1998; 27(2): 316-319.
47. Stroffolini T, Mele A, Tosti ME et al. The impact of the hepatitis B mass immunisation campaign on the incidence and risk factors of acute hepatitis B in Italy. J Hepatol 2000; 33(6): 980-985.
48. Giacchino R. Zancan L, Vajro P et al. Hepatitis B virus infection in native versus immigrant or adopted children in Italy following the compulsory vaccination. Infection 2001; 29(4): 188-191.
49. Da Villa G, Sepe A. Immunization program against hepatitis B virus infection in Italy: cost-effectiveness. Vaccine 1999; 17(13-14): 1734-1738.
50. Beutels P. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000). Health Econ 2001; 10(8): 751-774.
51. Deuson RR, Brodovicz KG, Barker L et al. Economic analysis of a child vaccination project among Asian Americans in Philadelphia, Pa. Arch Pediatr Adolesc Med 2001; 155(8): 909-914.
52. Malik AH, Lee WM. Chronic hepatitis B virus infection: treatment strategies for the next millennium. Ann Intern Med 2000; 132(9): 723-731.
53. Johnson MA, Moore KH, Yuen GJ et al. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet 1999; 36(1): 41-66.
54. Tassopoulus N, Hadziyannis S, Ideo G. Famciclovir treatment of anti-HBe chronic hepatitis B: results of a randomized, placebo-controlled study. J Hepatol 2002; 32: 102.
55. Carreno V, Marcellin P, Hadziyannis S et al. Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1999; 30(1): 277-282.
56. Perrillo RP, Schiff ER, Davis GL et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 1990; 323(5): 295-301.
57. Thomas HC, Lok AS, Carreno V et al. Comparative study of three doses of interferon-alpha 2a in chronic active hepatitis B. The International Hepatitis Trial Group. J Viral Hepat 1994; 1(2): 139-148.
58. Korenman J, Baker B, Waggoner J et al. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991; 114(8): 629-634.
59. Chen DK, Yim C, O'Rourke K et al. Long-term follow-up of a randomized trial of interferon therapy for chronic hepatitis B in a predominantly homosexual male population. J Hepatol 1999; 30(4): 557-563.
60. Ikeda K, Saitoh S, Suzuki Y et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study. Cancer 1998; 82(5): 827-835.
61. Fattovich G, Giustina G, Realdi G et al. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1997; 26(5): 1338-1342.
62. Brunetto MR, Oliveri F, Coco B et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002; 36(2): 263-270.
63. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339(2): 61-68.
64. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341(17): 1256-1263.
65. Schalm SW, Heathcote J, Cianciara J et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46(4): 562-568.
66. Song BC, Suh DJ, Lee HC et al. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32(4 Pt 1): 803-806.
67. Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001; 121(1): 101-109.
68. Oliveri F, Santantonio T, Bellati G et al. Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon. Am J Gastroenterol 1999; 94(5): 1366-1372.
69. Lampertico P, Del Ninno E, Manzin A et al. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 1997; 26(6): 1621-1625.
70. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negatlve chronic hepatitis B. J Hepatol 2001; 34(2): 306-313.
71. Santantonio T, Mazzola M, Iacovazzi T et al. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000; 32(2); 300-306.
72. Tassopoulos NC, Volpes R, Pastore G et al. Efficacy of lamivudine In patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999; 29(3): 889-896.
73. Hadziyannis SJ, Papatheodoridis GV, Dimou E et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32(4 Pt 1): 847-851.
74. Dienstag JL, Schiff ER, Mitchell M et al. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology 1999; 30(4): 1082-1087.
75. Liaw YF, Chien RN, Yeh CT et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30(2): 567-572.
76. Perrillo R, Schiff E, Yoshida E et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32(1): 129-134.
77. Gilson RJ, Chopra KB, Newell AM et al. A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. J Viral Hepat 1999; 6(5): 387-395.
78. Heathcote E, Jeffers L, Perillo R et al. Viral suppression and HBeAg+ seroconversion following long-term adefovir dipivoxil therapy in chronic hepatitis B infection. 52nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). November 9-13, 2001. Dallas, Texas.
79. Marcellin P, Chang TT, Lim SG et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348(9): 808-816.
80. Peters M, Hann H, Martin P et al. Adefovir dipivoxil (adv) alone and in combination with lamivudine (lam) suppresses lam-resistant hepatitis b virus (hbv) replication: 16 week interim analysis. J Hepatol Abstract 646. 37th Annual Meeting of the European Association for the Study of the Liver (EASL). April 18-22, 2002. Madrid, Spain.
81. Ono-Nita SK. Kato N, Shiratori Y et al. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J Clin Invest 1999; 103(12): 1635-1640.
82. Delaney WEt, Edwards R, Colledge D et al. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob Agents Chemother 2001; 45(6): 1705-1713.
83. Xiong S, Yang H, Westland C. Resistance surveillance of HBeAg-negative chronic hepatitis B (CHB) patients treated for two years with adefovir dipivoxil (ADV). 38th Annual Meeting of the European Association for the Study of the Liver (EASL). July 3-6, 2003. Geneva, Switzerland.
84. Tassopoulos N. Entecavir is effective in treating patients with chronic hepatitis B who have failed lamivudine therapy. Hepatology 2001; 34(340A).
85. Glue P, Fang JW, Rouzier-Panis R et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000; 68(5): 556-567.
86. Zeuzem S, Feinman SV, Rasenack J et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343(23): 1666-1672.
87. Heathcote EJ, Shiffman ML, Cooksley WG et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343(23): 1673-1680.
88. Reddy KR, Wright TL, Pockros PJ et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33(2): 433-438.
89. Lindsay KL, Trepo C, Heintges T et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34(2): 395-403.
90. Cooksley W, Piratvisuth T, Wang Y et al. Evidence for the efficacy of Peg-Interferon alfa 2A (40 Kd) (PEGASYS) in the treatment of HBeAntigen positive chronic hepatitis B and impact of baseline factors. 37th Annual Meeting of the European Association for the Study of the Liver (EASL). April 17-21, 2002. Madrid, Spain.